Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

Leqembi is expected to grow slowly – in part as a result of the negative hangover in sentiment that surrounded Aduhelm’s approval on controversial data, but also due to logistical hurdles ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high ...

INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

I remember the first time I was on stage and scrambled my words. If my lines in a play were supposed to be "Sherwin-Williams, ...

Sean "Diddy" Combs got a standing ovation from fellow inmates when the music mogul returned to jail after winning acquittals ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...